SOLANA BEACH, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty
pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial
results for the fourth quarter and full year ended December 31, 2016 on Wednesday, March 15, 2017, after the market closes.
Evoke will hold a conference call on Wednesday, March 15, 2017, at 4:30 pm ET to discuss the results.
Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast
of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com.
After the live webcast, the event will be archived on Evoke's website for one year. In addition, a telephonic
replay of the call will be available until March 22, 2017. The replay can be accessed by dialing 1-844-512-2921 (United States) or
1-412-317-6671 (International) with confirmation code 13656829.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders
and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and
recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers
worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide
is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and
intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through
nasal administration. Visit www.EvokePharma.com for more information.
Investor Contact: The Ruth Group Tram Bui Tel: 646-536-7035 tbui@theruthgroup.com
